Schedule 13G ownership disclosure

Apellis Pharmaceuticals Inc

Security class unavailable · CUSIP: 03753U106

Event date: 2019-03-20

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
2,309,052
Percent of class
12.1000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-19-016793
Form type
SC 13G/A
Filer
Kezar Life Sciences, Inc.
CIK
CIK 1645666
Filed
Mar 22, 2019
Reporting period
Mar 20, 2019
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub